Thermo Fisher Scientific Inc (NYSE:TMO)‘s stock had its “overweight” rating reaffirmed by research analysts at Barclays PLC in a research note issued to investors on Monday. They currently have a $215.00 price objective on the medical research company’s stock. Barclays PLC’s price target points to a potential upside of 14.18% from the stock’s current price.

A number of other brokerages have also recently commented on TMO. Zacks Investment Research cut shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Tuesday, September 12th. Cowen and Company reiterated an “outperform” rating and issued a $220.00 target price (up from $200.00) on shares of Thermo Fisher Scientific in a research report on Sunday, September 10th. Morgan Stanley reiterated an “overweight” rating and issued a $220.00 target price on shares of Thermo Fisher Scientific in a research report on Wednesday, September 6th. Bank of America Corporation reiterated a “buy” rating and issued a $210.00 target price (up from $200.00) on shares of Thermo Fisher Scientific in a research report on Friday, July 21st. Finally, Cleveland Research upgraded shares of Thermo Fisher Scientific from a “neutral” rating to a “buy” rating in a research report on Thursday, July 20th. One analyst has rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $195.33.

Thermo Fisher Scientific (NYSE TMO) opened at 188.30 on Monday. The stock has a market capitalization of $73.46 billion, a PE ratio of 32.80 and a beta of 1.05. The firm has a 50 day moving average of $181.07 and a 200-day moving average of $171.15. Thermo Fisher Scientific has a 52 week low of $139.07 and a 52 week high of $194.30.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, July 26th. The medical research company reported $2.30 EPS for the quarter, beating the Zacks’ consensus estimate of $2.27 by $0.03. The business had revenue of $5 billion during the quarter, compared to analysts’ expectations of $4.92 billion. Thermo Fisher Scientific had a net margin of 11.80% and a return on equity of 15.97%. The company’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same period in the prior year, the business earned $2.03 earnings per share. On average, equities analysts predict that Thermo Fisher Scientific will post $9.35 EPS for the current year.

TRADEMARK VIOLATION WARNING: “Thermo Fisher Scientific Inc (TMO) Earns “Overweight” Rating from Barclays PLC” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another publication, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/09/25/thermo-fisher-scientific-inc-tmo-earns-overweight-rating-from-barclays-plc.html.

In other news, Director Jim P. Manzi sold 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 17th. The shares were sold at an average price of $175.20, for a total value of $175,200.00. Following the completion of the transaction, the director now owns 38,757 shares of the company’s stock, valued at $6,790,226.40. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Jim P. Manzi sold 11,318 shares of the firm’s stock in a transaction that occurred on Friday, August 18th. The shares were sold at an average price of $172.94, for a total transaction of $1,957,334.92. Following the completion of the transaction, the director now directly owns 38,757 shares of the company’s stock, valued at approximately $6,702,635.58. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 52,738 shares of company stock valued at $9,302,112. 0.49% of the stock is currently owned by insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the company. BB&T Securities LLC boosted its stake in shares of Thermo Fisher Scientific by 4.4% in the first quarter. BB&T Securities LLC now owns 89,837 shares of the medical research company’s stock valued at $13,798,000 after purchasing an additional 3,819 shares during the period. Toronto Dominion Bank boosted its stake in shares of Thermo Fisher Scientific by 53.5% in the first quarter. Toronto Dominion Bank now owns 107,099 shares of the medical research company’s stock valued at $16,450,000 after purchasing an additional 37,307 shares during the period. Mitchell Capital Management Co. boosted its stake in shares of Thermo Fisher Scientific by 40.3% in the second quarter. Mitchell Capital Management Co. now owns 44,940 shares of the medical research company’s stock valued at $7,841,000 after purchasing an additional 12,910 shares during the period. IBM Retirement Fund boosted its stake in shares of Thermo Fisher Scientific by 117.7% in the second quarter. IBM Retirement Fund now owns 9,537 shares of the medical research company’s stock valued at $1,860,000 after purchasing an additional 5,157 shares during the period. Finally, Cornerstone Investment Partners LLC boosted its stake in shares of Thermo Fisher Scientific by 41.7% in the second quarter. Cornerstone Investment Partners LLC now owns 421,541 shares of the medical research company’s stock valued at $73,546,000 after purchasing an additional 123,954 shares during the period. 83.36% of the stock is owned by institutional investors and hedge funds.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Analyst Recommendations for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Stock Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related stocks with our FREE daily email newsletter.